Oncology Biosimilar Market Assessed & Forecast in Infiniti Research Report Now Available at MarketPublishers.com
02 Mar 2016 • by Natalie Aster
LONDON – Cancer represents an enormous burden to health care systems globally owing to high treatment costs. The patent expiry of a great number of drugs for cancer treatment facilitates the entry of biosimilars into the marketplace. Biosimilars are being incorporated into oncology clinical practices in the palliative care setting.
Globally, the oncology biosimilars market is projected to increase at 31.76% CAGR through to 2020. The rise in the number of patent expiries, increase in cancer prevalence, mushrooming ageing population, promising pharmaceutical pipeline, need for cost-effective therapy, and favourable government laws and regulations are amid the major factors driving the market growth. The market has also witnessed the emergence of biosimilars, surging number of strategic collaborations, outsourcing of biosimilar production activities, a hike in cancer awareness, and the increase in R&D activity, etc. However, risks pertaining to failure of drug products in the market, multiple production complexities, unwillingness of physicians to prescribe biosimilars, complex regulatory processes, restricted availability of biosimilar medicinal products, and risks of side effects.
Biocon, Celltrion, Dr. Reddy's Laboratories, F Hoffmann-La Roche, Hospira Mylan and Sandoz are some of the prominent market players.
Topical market research report “Global Oncology Biosimilars Market 2016-2020” created by Infiniti Research reviews the present-day scenario of, and the opportunities for growth in the global oncology biosimilars market over the period 2016-2020. The study looks into the biosimilar industry, covering a comparison of biosimilars with generic small molecules, factors impacting biologics and biosimilars, pricing and business strategies, factors influencing the adoption of biosimilars, market penetration of originators and biosimilars in various regions, etc. The report presents market size estimates by considering the revenue obtained from biosimilar sales in the global cancer market. It provides detailed market segmentation by end user and application, and explores the market performance across the various key regions like the USA, Europe, India, Japan and China. The research study also includes Porter’s 5 forces analysis; outlines market challenges, drivers, and key trends. It explores the vendor landscape and limelights the top vendors.
Global Oncology Biosimilars Market 2016-2020
Published: February, 2016
Price: US$ 3,000.00
More reports by this publisher are available at Infiniti Research page.